Skip to Content
Merck
All Photos(1)

Documents

MAB5412

Sigma-Aldrich

Anti-Indoleamine 2,3-dioxygenase Antibody, clone 10.1

clone 10.1, Chemicon®, from mouse

Synonym(s):

Indoleamine-pyrrole 2,3-dioxygenase

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

10.1, monoclonal

species reactivity

human

species reactivity (predicted by homology)

mouse, rat

manufacturer/tradename

Chemicon®

technique(s)

immunohistochemistry: suitable
western blot: suitable

isotype

IgG3

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... IDO1(3620)

General description

Indoleamine 2,3-dioxygenase (IDO) is an enzyme that is responsible for converting tryptophan to kynurenines. IDO is expressed by a wide variety of tissues and IDO can be upregulated by interferon gamma. IDO modulates levels of the amino acid tryptophan, which is vital for cell growth, but is also involved in the suppression of the immune response. IDO may be involved in the suppression of the immune response to tumours and blocking the IDO pathway may be a potential target for immunotherapy.

Specificity

Reacts with Indolamine 2,3-dioxygenase (IDO). Note IDO is usually expressed in response to various stimuli. A good positive control is HeLa cells stimulated with IFN-gamma, {http://www.upstate.com/browse/productdetail.q.ProductID.e.05-840#}.

Immunogen

Amino acids 78-184 of human IDO fused to GST.

Application

Anti-Indoleamine 2, 3-dioxygenase Antibody, clone 10.1 is an antibody against Indoleamine 2 for use in IH & WB.
Immunohistochemistry:
A previous lot of this antibody worked on lightly fixed tissues; Triton X-100 treatment only in the block, not with primary antibody. High temperature antigen retrieval is recommended.

Western blot:
Recognizes a 42-45kDa band in IFN-gamma treated human HeLa cell lines. Mouse IDO runs slightly smaller in blots than human IDO.

Optimal working dilutions must be determined by end user.
Research Category
Inflammation & Immunology
Research Sub Category
Inflammation & Autoimmune Mechanisms

Quality

Routinely evaluated by Western Blot on untreated and IFNgamma treated HeLa lysates.

Western blot:
1:500 dilution of this lot detected IDO on 10 μg of untreated and IFN gamma treated HeLa lysates.

Target description

42-45kDa

Linkage

Replaces: AB5968

Physical form

Format: Purified
Protein A purified
Purified mouse monoclonal IgG3 in buffer containing 0.02 M phosphate, 0.25 M NaCl, 0.1% NaN3, pH 7.6.

Storage and Stability

Stable for 6 months at 2-8ºC in undiluted aliquots from date of receipt.

Analysis Note

Control
IFN-gamma stimulated human peripheral blood lymphocytes, HeLa lysates.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Davide Matino et al.
The Journal of clinical investigation, 125(10), 3766-3781 (2015-10-02)
The development of inhibitory antibodies to factor VIII (FVIII) is a major obstacle in using this clotting factor to treat individuals with hemophilia A. Patients with a congenital absence of FVIII do not develop central tolerance to FVIII, and therefore
Sung Hoon Sim et al.
Cancer science, 103(2), 155-160 (2011-11-24)
There is no specific marker to evaluate the immuno-suppressive status of cancer patients. Several markers, such as CD124, latency-associated peptide (LAP), arginase I, indole-amine-2,3-dioxygenase (IDO) and inducible nitric oxide synthase (iNOS), are known to be associated with immune suppression. However
Antonella De Luca et al.
PLoS pathogens, 9(7), e1003486-e1003486 (2013-07-16)
The ability to tolerate Candida albicans, a human commensal of the gastrointestinal tract and vagina, implicates that host defense mechanisms of resistance and tolerance cooperate to limit fungal burden and inflammation at the different body sites. We evaluated resistance and
Serum analysis of tryptophan catabolism pathway: correlation with Crohn's disease activity.
Gupta, NK; Thaker, AI; Kanuri, N; Riehl, TE; Rowley, CW; Stenson, WF; Ciorba, MA
Inflammatory bowel diseases null
Antonio Curti et al.
Blood, 109(7), 2871-2877 (2006-12-14)
Indoleamine 2,3-dioxygenase (IDO) is a novel immunosuppressive agent expressed in some subsets of normal and neoplastic cells, including acute myeloid leukemia (AML) cells. Here, we show that IDO expression correlates with increased circulating CD4+CD25+FOXP3+ T cells in patients with AML

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service